Stereotactic body radiotherapy beneficial for COPD patients with localised NSCLC
Non-small cell lung cancer (NSCLC) is a cause of considerable mortality and morbidity but, for patients staged T1-2N0M0, surgical resection can be curative.
Unfortunately, surgical operability and success are often compromised by the presence of co-existing conditions. Chronic obstructive pulmonary disease (COPD) and NSCLC are often co-morbid diseases with up to 70% of patients experiencing both conditions associated with poor prognoses.
The aim of this Danish study was to compare survival in COPD patients with localised NSCLC who were treated with stereotactic body radiotherapy (the NSCLC group), with COPD patients without a diagnosis of cancer (the non-malignant control group).
Data from 102 NSCLC patients were collected prospectively; data from 572 suitable non-malignant patients were collected retrospectively from a review of medical records. The primary endpoint of the evaluation was overall survival.
Want to read more?
Unlock full access to RCNi Plus today
Save over 50% on your first three months:
- Customisable clinical dashboard featuring 200+ topics
- Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
- RCNi Learning featuring 180+ RCN accredited learning modules
- NMC-compliant RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests